FDA Clears Two IND Applications for Fortis Therapeutics Novel Anti-CD46 Candidate for Prostate Cancer and Multiple Myeloma

FDA Clears Two IND Applications for Fortis Therapeutics Novel Anti-CD46 Candidate for Prostate Cancer and Multiple Myeloma

Source: 
CP Wire
snippet: 

Fortis Therapeutics, Inc., an immuno-oncology biotech developing a novel antibody-drug conjugate (ADC) against CD46, today announced the U.S. Food and Drug Administration (FDA) has cleared two investigational new drug (IND) applications for the company’s lead candidate, FOR46, for the treatment of metastatic castration-resistant prostate cancer and late-stage multiple myeloma.